WO2016160976A3 - Monovalent tnf binding proteins - Google Patents

Monovalent tnf binding proteins Download PDF

Info

Publication number
WO2016160976A3
WO2016160976A3 PCT/US2016/024992 US2016024992W WO2016160976A3 WO 2016160976 A3 WO2016160976 A3 WO 2016160976A3 US 2016024992 W US2016024992 W US 2016024992W WO 2016160976 A3 WO2016160976 A3 WO 2016160976A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
tnf binding
monovalent tnf
monovalent
treatment
Prior art date
Application number
PCT/US2016/024992
Other languages
French (fr)
Other versions
WO2016160976A2 (en
Inventor
Tariq Ghayur
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of WO2016160976A2 publication Critical patent/WO2016160976A2/en
Publication of WO2016160976A3 publication Critical patent/WO2016160976A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided are TNF binding proteins and methods of treatment using the same. Also provided are nucleic acids encoding the binding proteins and recombinant expression vectors and host cells for making such binding proteins.
PCT/US2016/024992 2015-03-30 2016-03-30 Monovalent tnf binding proteins WO2016160976A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562140155P 2015-03-30 2015-03-30
US62/140,155 2015-03-30

Publications (2)

Publication Number Publication Date
WO2016160976A2 WO2016160976A2 (en) 2016-10-06
WO2016160976A3 true WO2016160976A3 (en) 2016-11-10

Family

ID=56842994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/024992 WO2016160976A2 (en) 2015-03-30 2016-03-30 Monovalent tnf binding proteins

Country Status (1)

Country Link
WO (1) WO2016160976A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2023092048A1 (en) * 2021-11-18 2023-05-25 Adafre Biosciences, Llc Anti-tnf-alpha antibodies and compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102251A2 (en) * 2009-03-05 2010-09-10 Abbott Laboratories Il-17 binding proteins
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2015014979A1 (en) * 2013-08-01 2015-02-05 F. Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230574A3 (en) 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
ES2096553T3 (en) 1988-12-19 1997-03-16 American Cyanamid Co METHOD FOR THE TREATMENT OF ENDOTOXIC SHOCK IN A MAMMAL ANIMAL.
GB8921123D0 (en) 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
AU646695B2 (en) 1990-04-09 1994-03-03 Immunex Corporation Isolated viral protein cytokine antagonists
DE4037604A1 (en) 1990-04-25 1991-10-31 Bayer Ag Use of anti-TNF antibodies to treat ischaemia and its sequelae - esp. to increase survival rate after myocardial infarct and transplants
CA2288429C (en) 1991-03-15 2006-04-25 Synergen, Inc. Pegylation of polypeptides
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
AU3244693A (en) 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993019751A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
EP0585705B1 (en) 1992-08-28 1998-11-04 Bayer Corporation Use of monoclonal antibodies to TNF to treat bacterial meningitis
DE4307508A1 (en) 1993-03-10 1994-09-15 Knoll Ag Use of anti-TNF antibodies as a medicine in the treatment of heart failure (heart muscle weakness)
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
ES2340112T3 (en) 1998-04-20 2010-05-28 Glycart Biotechnology Ag ANTIBODY GLICOSILATION ENGINEERING FOR THE IMPROVEMENT OF DEPENDENT CELLULAR CYTOTOXICITY OF ANTIBODIES.
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
JP2005503789A (en) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー Anti-Aβ antibody
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
CA2562772A1 (en) 2004-04-15 2005-10-27 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102251A2 (en) * 2009-03-05 2010-09-10 Abbott Laboratories Il-17 binding proteins
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2015014979A1 (en) * 2013-08-01 2015-02-05 F. Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIGIAMMARINO E L ET AL: "Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design", MABS, LANDES BIOSCIENCE, US, vol. 3, no. 5, 1 September 2011 (2011-09-01), pages 487 - 494, XP009168882, ISSN: 1942-0862, DOI: 10.4161/MABS.3.5.16326 *
JENS A. A. FISCHER ET AL: "Combined Inhibition of Tumor Necrosis Factor [alpha] and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody", ARTHRITIS & RHEUMATOLOGY, vol. 67, no. 1, 1 January 2015 (2015-01-01), pages 51 - 62, XP055213940, ISSN: 2326-5191, DOI: 10.1002/art.38896 *
S. METZ ET AL: "Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing", PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 25, no. 10, 1 October 2012 (2012-10-01), pages 571 - 580, XP055069824, ISSN: 1741-0126, DOI: 10.1093/protein/gzs064 *
SPIESS CHRISTOPH ET AL: "Alternative molecular formats and therapeutic applications for bispecific antibodies", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 67, no. 2, 27 January 2015 (2015-01-27), pages 95 - 106, XP029246892, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2015.01.003 *

Also Published As

Publication number Publication date
WO2016160976A2 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
TWI799368B (en) Anti-tl1a antigen binding proteins and related nucleic acids, expression vectors, host cells, pharmaceutical composition, methods and uses
SG10202110491PA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
IL258102A (en) Transmembrane immunumodulatory proteins comprising variant immunuglobulin superfamily domains, nucleic acids encoding same, vectors and cells expressing same and uses thereof
EP3950941A3 (en) Dnase polypeptide variants
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
MX2017008817A (en) Compositions and methods for protein glycosylation.
WO2015048333A3 (en) Nutritive polypeptides and formulations thereof, and methods of production and use thereof
MX2023007211A (en) Anti-myostatin antibodies and methods of use.
IL258202B (en) Cd3-binding polypeptides, method for their preparation, pharmaceutical compositions, nucleic acids, vectors and use of such polypeptides
WO2015109124A3 (en) Immunomodulatory agents
MX2017014908A (en) Trispecific binding proteins and methods of use.
EP3318579A4 (en) Interleukin 15 fusion protein for tumor target therapy
WO2016046778A3 (en) Protease-activatable bispecific proteins
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
WO2014116846A3 (en) Methods and compositions for modulating an immune response
EP3883954A4 (en) Recombinant viral vectors and nucleic acids for producing the same
MX2016012479A (en) Binding members to tnf alpha.
EP3551212A4 (en) Novel recombinant klotho proteins and compositions and methods involving the same
WO2014152247A8 (en) Improved tnf binding proteins
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
WO2017087827A8 (en) Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria
WO2017040329A3 (en) Peptides binding to bfl-1

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16757987

Country of ref document: EP

Kind code of ref document: A2